[go: up one dir, main page]

CN111437248A - A kind of Yichangshou oral liquid and its preparation method and application - Google Patents

A kind of Yichangshou oral liquid and its preparation method and application Download PDF

Info

Publication number
CN111437248A
CN111437248A CN202010187906.4A CN202010187906A CN111437248A CN 111437248 A CN111437248 A CN 111437248A CN 202010187906 A CN202010187906 A CN 202010187906A CN 111437248 A CN111437248 A CN 111437248A
Authority
CN
China
Prior art keywords
oral liquid
intestine
yichangshou
benefiting
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010187906.4A
Other languages
Chinese (zh)
Inventor
黄德娟
胡志勇
吕朋
陈天阳
魏科
叶梓芳
严来清
李丽琦
雷胜
李�昊
杨世文
田召浚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China Institute of Technology
Original Assignee
East China Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China Institute of Technology filed Critical East China Institute of Technology
Priority to CN202010187906.4A priority Critical patent/CN111437248A/en
Publication of CN111437248A publication Critical patent/CN111437248A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/722Chitin, chitosan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/21Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482Cassia, e.g. golden shower tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/65Paeoniaceae (Peony family), e.g. Chinese peony
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C2240/00Use or particular additives or ingredients
    • A23C2240/15Use of plant extracts, including purified and isolated derivatives thereof, as ingredient in dairy products
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The application discloses intestine-benefiting life oral liquid and a preparation method and application thereof, and the prepared intestine-benefiting life oral liquid is suitable for middle-aged and elderly people in a sub-health state. The intestine-benefiting life-prolonging oral liquid has double functions, and on one hand, the intestinal-benefiting life-prolonging oral liquid can promote discharge of heavy metals such as cadmium, lead and the like accumulated in an organism and reduce the toxicity of the heavy metals to the organism; on the other hand, the lactobacillus and bifidobacterium which are intestinal probiotics have obvious proliferation effect, and are beneficial to middle-aged and elderly people in sub-health state to enhance the immunity of the organism and improve the physiological condition of the organism by proliferating the intestinal probiotics. The intestine-benefiting life-prolonging oral liquid is low in cost, free of toxic and side effects and capable of being widely popularized and used.

Description

一种益肠寿口服液及其制备方法与应用A kind of Yichangshou oral liquid and its preparation method and application

技术领域technical field

本申请涉及重金属促排技术领域,尤其涉及一种益肠寿口服液及其制备方法与应用。The application relates to the technical field of excretion promotion of heavy metals, in particular to a Yichangshou oral liquid and a preparation method and application thereof.

背景技术Background technique

随着我国工业发展,工业“三废”对环境污染日益严重,特别是重金属污染,会给整个生物链及生态系统造成很大的危害。一些有毒有害物质如镉、铅等重金属可以迁移至水体、土壤,经食物链进入人体,对人体健康带来蓄积性危害;此外,重金属还可通过雾霾以及粉尘中的颗粒物(PM2.5)经呼吸道进入人体。With the development of my country's industry, the industrial "three wastes" are increasingly polluting the environment, especially heavy metal pollution, which will cause great harm to the entire biological chain and ecosystem. Some toxic and harmful substances such as cadmium, lead and other heavy metals can migrate to water and soil, enter the human body through the food chain, and bring cumulative harm to human health; in addition, heavy metals can also pass through haze and particulate matter (PM2.5) in dust. The respiratory tract enters the human body.

虽然我国要求工业“三废”必须进行净化处理并达标排放,但“三废”污染依然严峻。 据统计,全球每年向环境中释放的镉达3万吨左右,其中82%~94%的镉会进入到土壤中,土 壤中的镉通过水体、农作物或鱼虾类进入人体或牲畜机体内,可通过生物富集作用,积聚于 人体或牲畜内脏器官,从而对肾脏、骨骼等器官组织造成严重伤害。例如,19世纪60年代 发生在日本的“骨痛病”,就是镉(cadmium,Cd)通过食物链进入人体,镉的毒性较大,被 镉污染的空气和食物对人体危害严重,且在人体内代谢较慢,即身体积聚过量的镉损坏肾小 管功能,造成体内蛋白质从尿中流失,而且年龄越大积聚越多,另外,镉还可取代机体内的 钙,久而久之形成软骨症和自发性骨折。Although my country requires that the industrial "three wastes" must be purified and discharged up to the standard, the pollution of the "three wastes" is still severe. According to statistics, the world releases about 30,000 tons of cadmium into the environment every year, of which 82% to 94% of the cadmium will enter the soil. It can accumulate in the internal organs of human or livestock through bioconcentration, thereby causing serious damage to organs such as kidneys and bones. For example, in the 1860s in Japan, the "Bone-Itai Disease", that is, cadmium (cadmium, Cd) entered the human body through the food chain. Cadmium is highly toxic, and the air and food polluted by cadmium are seriously harmful to the human body. Slow metabolism, that is, excessive accumulation of cadmium in the body damages the renal tubular function, causing the loss of protein in the body from the urine, and the accumulation of cadmium increases with age. In addition, cadmium can also replace calcium in the body, resulting in osteomalacia and spontaneous fractures over time .

对于铅(Plumbum,Pb)中毒,其不仅多发于儿童,其对成年人伤害也是很严重的,会引起神经系统、消化系统、血液系统、心血管系统、肾功能损坏、生殖系统受损等疾病,日益引起社会广泛关注。For lead (Plumbum, Pb) poisoning, it is not only more common in children, but also seriously harms adults, causing diseases such as nervous system, digestive system, blood system, cardiovascular system, kidney function damage, reproductive system damage and other diseases , has attracted widespread attention of the society.

目前,对于人体内重金属含量的关注较少,一般仅在人体出现重金属中毒症状时,才进行相关的治疗工作,此时,人体内重金属的含量多已严重超标、且已对人体机体造成损伤,且较多损伤不可逆转。因此,为减少重金属对人体造成的损伤,应防止重金属在人体内长期积累,特别是处于亚健康状态的中老年人,对于进入身体的重金属进行定期的排放,将人体的重金属含量控制在标准范围之内,从而避免人体出现重金属中毒的问题。At present, less attention is paid to the content of heavy metals in the human body. Generally, the relevant treatment work is only carried out when the human body has symptoms of heavy metal poisoning. At this time, the content of heavy metals in the human body has seriously exceeded the standard and caused damage to the human body. And more damage is irreversible. Therefore, in order to reduce the damage caused by heavy metals to the human body, it is necessary to prevent the long-term accumulation of heavy metals in the human body, especially the middle-aged and elderly people in sub-health state, regularly discharge the heavy metals that enter the body, and control the content of heavy metals in the human body within the standard range In order to avoid the problem of heavy metal poisoning in the human body.

但是,现在市场上没有适用于处于亚健康状态的中老年人群、且可对多种重金属均具有促排作用的重金属促排产品。因此,亟待一种适用于处于亚健康状态的中老年人群、且可同时促排多种重金属的重金属解毒药剂。However, there is currently no heavy metal excretion-promoting product on the market that is suitable for the middle-aged and elderly people in sub-health state and can promote excretion of various heavy metals. Therefore, there is an urgent need for a heavy metal detoxification agent that is suitable for middle-aged and elderly people in sub-health state and can simultaneously promote the excretion of various heavy metals.

发明内容SUMMARY OF THE INVENTION

本申请提供了一种益肠寿口服液及其制备方法与应用,以解决现在市场上没有适用于处于亚健康状态的中老年人群、且可对多种重金属均具有促排作用的重金属促排产品的问题。The application provides a Yichangshou oral liquid and its preparation method and application, so as to solve the problem that there is no heavy metal excretion promoting effect on the market that is suitable for middle-aged and elderly people in a sub-health state and can promote the excretion of various heavy metals. product problem.

第一方面,本申请提供了一种益肠寿口服液,包括有效成分、辅料成分以及溶剂,其中有效成分包括羧甲基壳聚糖、β-环糊精、低聚果糖以及水苏糖,辅料成分包括白芍、枳壳、生地、草决明、茯苓以及莱菔子,溶剂为水。In a first aspect, the application provides a Yichangshou oral liquid, comprising active ingredients, auxiliary ingredients and a solvent, wherein the active ingredients include carboxymethyl chitosan, β-cyclodextrin, fructooligosaccharides and stachyose, The auxiliary ingredients include white peony root, citrus aurantium, raw land, cassia, tuckahoe and radish, and the solvent is water.

可选地,羧甲基壳聚糖、β-环糊精、低聚果糖以及水苏糖的质量比为1:1:2:1;白芍、枳壳、生地、草决明、茯苓以及莱菔子的质量比为1:1:1.5:1.5:1.5:2。Optionally, the mass ratio of carboxymethyl chitosan, β-cyclodextrin, oligofructose and stachyose is 1:1:2:1; Paeonia lactiflora, Citrus aurantium, Helicobacter, Cassia, Poria and The mass ratio of raisins is 1:1:1.5:1.5:1.5:2.

可选地,有效成分包括以下重量份的原料:羧甲基壳聚糖5g、β-环糊精5g、低聚果糖10g、水苏糖5g;辅料成分包括以下重量份的原料:白芍5g,枳壳5g,生地7.5g,草决明7.5g,茯苓7.5g,莱菔子10g。Optionally, the active ingredients include the following raw materials by weight: carboxymethyl chitosan 5g, β-cyclodextrin 5g, fructooligosaccharide 10g, stachyose 5g; the adjuvant components include the following raw materials by weight: Paeonia lactiflora 5g , Citrus aurantium 5g, raw land 7.5g, Cassia 7.5g, Poria 7.5g, Radix radish 10g.

可选地,溶剂的量为200-300ml。Optionally, the amount of solvent is 200-300 ml.

第二方面,本申请还提供了一种制备上述益肠寿口服液方法,包括辅料粉碎与混合、制备药液、引入有效成分、粘度控制以及灭菌工艺。In a second aspect, the present application also provides a method for preparing the above-mentioned Yichangshou oral liquid, including pulverizing and mixing auxiliary materials, preparing medicinal liquid, introducing active ingredients, viscosity control and sterilization processes.

其中,辅料粉碎与混合工序具体包括:将辅料成分中的白芍、枳壳、生地、草决明、茯苓以及莱菔子进行粉碎,投入混合机中进行均匀混合,得到混合辅料;Wherein, the pulverizing and mixing process of the auxiliary materials specifically includes: pulverizing the Paeonia lactiflora, Citrus aurantium, raw land, Cassia, Poria and Radix Radix in the auxiliary material components, and putting them into a mixer for uniform mixing to obtain mixed auxiliary materials;

制备药液工序具体包括:在混合辅料中加入适量水进行煎煮,煎煮温度保持在80℃到95℃之间,煎煮时间为1小时左右,经过滤去除药渣,获取上层的药液;The process of preparing the medicinal liquid specifically includes: adding an appropriate amount of water to the mixed auxiliary materials for decocting, maintaining the decocting temperature between 80°C and 95°C, and decocting for about 1 hour, removing the medicinal residues by filtration, and obtaining the upper medicinal liquid. ;

引入有效成分工序具体包括:在获取的药液加入羧甲基壳聚糖、β-环糊精、低聚果糖以及水苏糖,充分搅拌至有效成分溶解至药液中,制得口服原液;The process of introducing the active ingredients specifically includes: adding carboxymethyl chitosan, β-cyclodextrin, fructooligosaccharides and stachyose to the obtained medicinal liquid, and fully stirring until the active ingredients are dissolved in the medicinal liquid to prepare an oral stock solution;

粘度控制工艺具体包括:调整口服原液的粘度,制得口服液;The viscosity control process specifically includes: adjusting the viscosity of the oral stock solution to prepare the oral solution;

灭菌工艺具体包括:对口服液进行灭菌处理,其中,灭菌时间为10-30分钟,灭菌温度为110-130℃,灭菌压力为1.0-1.2kpa。The sterilization process specifically includes: sterilizing the oral liquid, wherein the sterilization time is 10-30 minutes, the sterilization temperature is 110-130° C., and the sterilization pressure is 1.0-1.2kpa.

第三方面,本申请还提供了一种上述益肠寿口服液的应用,益肠寿口服液用于奶制品或中老年保健品内的有益添加成分。In a third aspect, the application also provides an application of the above-mentioned Yichangshou oral liquid, which is used as a beneficial additive in dairy products or health care products for the middle-aged and elderly.

本申请提供了一种益肠寿口服液及其制备方法与应用,制备的益肠寿口服液适用于处于亚健康状态的中老年人群。本申请的益肠寿口服液具有双重作用,一方面,可对镉、铅等重金属的吸附、促排,降低重金属对机体的毒害;另一方面,服用益肠寿口服液可对肠道益生菌乳杆菌、双歧杆菌有显著的增殖效果,有助于处于亚健康状态的中老年人群通过增殖肠道益生菌增强机体免疫力,改善机体生理状况。另外,本申请的益肠寿口服液成本低、无毒副作用,可广泛推广使用。The application provides a Yichangshou oral liquid and a preparation method and application thereof, and the prepared Yichangshou oral liquid is suitable for middle-aged and elderly people in sub-health state. The Yichangshou oral liquid of the present application has dual functions. On the one hand, it can adsorb and promote the excretion of heavy metals such as cadmium and lead, and reduce the toxicity of heavy metals to the body; The bacteria Lactobacillus and Bifidobacterium have significant proliferation effect, which helps the middle-aged and elderly people in sub-health state to enhance the immunity of the body and improve the physiological condition of the body by proliferating intestinal probiotics. In addition, the Yichangshou oral liquid of the present application has low cost, no toxic and side effects, and can be widely used.

附图说明Description of drawings

为了更清楚地说明本申请的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,对于本领域普通技术人员而言,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to illustrate the technical solutions of the present application more clearly, the accompanying drawings required in the embodiments will be briefly introduced below. Obviously, for those of ordinary skill in the art, without creative work, the Additional drawings can be obtained from these drawings.

图1为本申请益肠寿口服液制备方法的流程图,Fig. 1 is the flow chart of the preparation method of Yichangshou oral liquid of the application,

图2为Pb标准曲线;Figure 2 is the Pb standard curve;

图3为Cd标准曲线;Figure 3 is a Cd standard curve;

图4为铅中毒试验中,各组小鼠在四周内体重变化图;Fig. 4 is a graph of changes in body weight of each group of mice within four weeks in the lead poisoning test;

图5为铅中毒试验中,各组小鼠在四周内肠道菌群变化图;Figure 5 is a graph of changes in the intestinal flora of mice in each group within four weeks in the lead poisoning test;

图6为铅中毒试验中,各组小鼠在四周内肾脏中铅含量变化图;Fig. 6 is a graph showing the change of lead content in the kidneys of each group of mice within four weeks in the lead poisoning test;

图7为镉中毒试验中,各组小鼠在四周内体重变化图;Fig. 7 is a graph of changes in body weight of mice in each group within four weeks in the cadmium poisoning test;

图8为镉中毒试验中,各组小鼠在四周内肠道菌群变化图;Figure 8 is a graph of changes in the intestinal flora of mice in each group within four weeks in the cadmium poisoning test;

图9为镉中毒试验中,各组小鼠在四周内肾脏镉含量的变化图。Figure 9 is a graph showing the changes of cadmium content in the kidneys of mice in each group within four weeks in the cadmium poisoning test.

具体实施方式Detailed ways

本申请提供一种益肠寿口服液,适用于处于亚健康状态的中老年人群,可对镉、铅等重金属的吸附、促排,降低重金属对机体的毒害。The application provides a Yichangshou oral liquid, which is suitable for middle-aged and elderly people in a sub-health state, and can adsorb and promote the excretion of heavy metals such as cadmium and lead, and reduce the toxicity of heavy metals to the body.

本申请提供的益肠寿口服液包括有效成分、辅料成分以及溶剂,其中有效成分包括羧甲基壳聚糖、β-环糊精、低聚果糖以及水苏糖,辅料成分包括白芍、枳壳、生地、草决明、茯苓以及莱菔子,溶剂为水。The Yichangshou oral liquid provided in this application includes active ingredients, auxiliary ingredients and solvents, wherein the active ingredients include carboxymethyl chitosan, β-cyclodextrin, fructooligosaccharides and stachyose, and the auxiliary ingredients include white peony root, citrus aurantium Shell, habitat, Cassia, Poria and Radix, the solvent is water.

其中,有效成分中,羧甲基壳聚糖和β-环糊精二种保健物质主要功能是促排体内重金属,增强机体免疫力,促进肠道内益生菌乳杆菌的增殖,乳杆菌是人体肠道中正常的优势细菌,有利于宿主消化和吸收,可以抑制病原菌,增加肠道中淋巴细胞数,增强机体免疫力。低聚果糖和水苏糖的主要功效是促进肠道益生菌双歧杆菌增殖,提高机体免疫力。Among them, among the active ingredients, the main functions of carboxymethyl chitosan and β-cyclodextrin are to promote the excretion of heavy metals in the body, enhance the immunity of the body, and promote the proliferation of probiotic Lactobacillus in the intestine. The normal dominant bacteria in the tract are beneficial to the host's digestion and absorption, can inhibit pathogenic bacteria, increase the number of lymphocytes in the intestinal tract, and enhance the body's immunity. The main effect of fructooligosaccharides and stachyose is to promote the proliferation of intestinal probiotics bifidobacteria and improve the immunity of the body.

辅助成分中,“白芍”具有调解肝脾不和、头痛眩晕的功效;“枳壳”在中老年人食积不化、脘腹胀满疼痛具有较好功效;“生地”主要功效是清热、通便、保肝、抗肿瘤,提高免疫力;“草决明”主要功效是明目、利胆保肝、润肠通便;“茯苓”主要功效是利水消肿,渗湿,健脾,宁心;“莱菔子”对食积气滞,咳喘痰多,胸闷食少的人群具有较好功效。Among the auxiliary components, "white peony root" has the effect of regulating liver and spleen disharmony, headache and dizziness; "citrus aurantium" has a good effect on middle-aged and elderly people's food accumulation, abdominal distention and pain; Defecation, liver protection, anti-tumor, improve immunity; "Cassiae" main effect is to improve eyesight, gallbladder and liver protection, laxative; Heart; "Radix radish" has a good effect on people with food accumulation and stagnation of qi, cough and phlegm, chest tightness and less food.

本实例中,羧甲基壳聚糖、β-环糊精、低聚果糖以及水苏糖的质量比为1:1:2:1;白芍、枳壳、生地、草决明、茯苓以及莱菔子的质量比为1:1:1.5:1.5:1.5:2。In this example, the mass ratio of carboxymethyl chitosan, β-cyclodextrin, oligofructose and stachyose is 1:1:2:1; Paeonia lactiflora, Citrus aurantium, Helicobacter, Cassia, Poria and The mass ratio of raisins is 1:1:1.5:1.5:1.5:2.

本实例中,有效成分包括以下重量份的原料:羧甲基壳聚糖5g、β-环糊精5g、低聚果糖10g、水苏糖5g;辅料成分包括以下重量份的原料:白芍5g,枳壳5g,生地7.5g,草决明7.5g,茯苓7.5g,莱菔子10g。In this example, the active ingredients include the following raw materials by weight: 5 g of carboxymethyl chitosan, 5 g of β-cyclodextrin, 10 g of fructooligosaccharides, and 5 g of stachyose; the auxiliary ingredients include the following raw materials by weight: 5 g of peony root , Citrus aurantium 5g, raw land 7.5g, Cassia 7.5g, Poria 7.5g, Radix radish 10g.

本实例中,溶剂的量为200-300ml,本领域技术人员可根据实际需要调整溶剂的量,例如250ml,其属于本申请的保护范围。In this example, the amount of solvent is 200-300ml, and those skilled in the art can adjust the amount of solvent according to actual needs, for example, 250ml, which belongs to the protection scope of the present application.

本申请还提供一种制备上述益肠寿口服液的方法,图1为本申请益肠寿口服液制备方法的流程图,如图1所示,益肠寿口服液制备方法包括辅料粉碎与混合、制备药液、引入有效成分、粘度控制以及灭菌工艺。The present application also provides a method for preparing the above-mentioned Yichangshou oral liquid. FIG. 1 is a flowchart of the preparation method of the Yichangshou oral liquid of the application. As shown in FIG. 1 , the preparation method of the Yichangshou oral liquid includes crushing and mixing of auxiliary materials. , Preparation of liquid medicine, introduction of active ingredients, viscosity control and sterilization process.

其中,步骤100,辅料粉碎与混合工序具体包括:将辅料成分中的白芍、枳壳、生地、草决明、茯苓以及莱菔子进行粉碎,投入混合机中进行均匀混合,得到混合辅料;Wherein, in step 100, the pulverizing and mixing process of the auxiliary materials specifically includes: pulverizing the Paeonia suffruticosa, Citrus aurantium, raw land, Cassia, Poria and Radix Radix in the auxiliary material components, and putting them into a mixer for uniform mixing to obtain mixed auxiliary materials;

步骤200,制备药液工序具体包括:在混合辅料中加入适量水进行煎煮,煎煮温度保持在80℃到95℃之间,煎煮时间为1小时左右,经过滤去除药渣,获取上层的药液;Step 200, the process of preparing the medicinal liquid specifically includes: adding an appropriate amount of water to the mixed auxiliary materials for decoction, the decoction temperature is kept between 80 ° C and 95 ° C, the decoction time is about 1 hour, the medicinal residue is removed by filtration, and the upper layer is obtained. the medicinal solution;

步骤300,引入有效成分工序具体包括:在获取的药液加入羧甲基壳聚糖、β-环糊精、低聚果糖以及水苏糖,充分搅拌至有效成分溶解至药液中,制得口服原液;Step 300, the process of introducing the active ingredients specifically includes: adding carboxymethyl chitosan, β-cyclodextrin, fructooligosaccharides and stachyose to the obtained medicinal solution, and fully stirring until the active ingredients are dissolved in the medicinal solution to prepare the solution. Oral solution;

步骤400,粘度控制工艺具体包括:调整口服原液的粘度,制得口服液。应当说明,羧甲基壳聚糖、β-环糊精具有成膜的特性,在药液中加入羧甲基壳聚糖、β-环糊精后,为防止粘度过大,需调整口服原液的粘度。本领域技术人员可根据实际需要,设置口服原液的粘度,例如120mPa.s、100mPa.s或80mPa.s,其属于本申请的保护范围。目前调整口服液粘度的方法有多种,例如,水稀释是最常用的方法,当然可加入可食用的稀释剂,均属于本申请的保护范围。In step 400, the viscosity control process specifically includes: adjusting the viscosity of the oral liquid to prepare the oral liquid. It should be noted that carboxymethyl chitosan and β-cyclodextrin have film-forming properties. After adding carboxymethyl chitosan and β-cyclodextrin to the medicinal solution, in order to prevent the viscosity from being too large, the oral stock solution needs to be adjusted. viscosity. Those skilled in the art can set the viscosity of the oral stock solution according to actual needs, for example, 120 mPa.s, 100 mPa.s or 80 mPa.s, which belongs to the protection scope of the present application. At present, there are various methods for adjusting the viscosity of the oral liquid. For example, water dilution is the most commonly used method. Of course, edible diluents can be added, which all belong to the protection scope of the present application.

步骤500,灭菌工艺具体包括:对口服液进行灭菌处理,其中,灭菌时间为10-30分钟,灭菌温度为110-130℃,灭菌压力为1.0-1.2kpa;应当说明,本领域技术人员可根据实际需要选择适宜的灭菌条件,例如灭菌时间为20分钟,灭菌温度为120℃,灭菌压力为1.1kpa,其均属于本申请的保护范围。Step 500, the sterilization process specifically includes: sterilizing the oral liquid, wherein the sterilization time is 10-30 minutes, the sterilization temperature is 110-130°C, and the sterilization pressure is 1.0-1.2kpa; Those skilled in the art can select suitable sterilization conditions according to actual needs, for example, the sterilization time is 20 minutes, the sterilization temperature is 120°C, and the sterilization pressure is 1.1 kpa, all of which belong to the protection scope of the present application.

本实例中,本申请的益肠寿口服液的制备方法还包括将干燥完毕的益肠寿口服液放入符合卫生食品安全标准的塑料包装瓶中,进行包装。In this example, the preparation method of the Yichangshou oral liquid of the present application further includes putting the dried Yichangshou oral liquid into a plastic packaging bottle that meets the hygienic food safety standard for packaging.

本申请还提供了一种上述益肠寿口服液的应用,益肠寿口服液用于奶制品或中老年保健品内的有益添加成分。益肠寿口服液作为一种有益成分,可添加至奶制品或中老年保健品内。The application also provides an application of the above-mentioned Yichangshou oral liquid, which is used as a beneficial additive component in dairy products or health care products for middle-aged and elderly people. As a beneficial ingredient, Yichangshou Oral Liquid can be added to dairy products or health care products for middle-aged and elderly people.

为验证本申请的益肠寿口服液对镉、铅等重金属的体内促排的效果,以下将以小白鼠为实验材料进行试验。In order to verify the effect of the Yichangshou oral liquid of the present application on promoting the excretion of heavy metals such as cadmium and lead in the body, the following experiments will be carried out with mice as experimental materials.

1、重金属染毒小鼠模型建立1. Establishment of a mouse model of heavy metal exposure

1.1 灌胃益肠寿口服液1.1 Gavage Yichangshou Oral Liquid

(1)分组(1) Grouping

将112只小鼠随机分为7组:一组空白组、三组中毒组和三组试验组,每组小鼠各16只。空白组灌胃生理盐水2周,中毒组和试验组分别灌胃Pb、Cd溶液2周,每周结束后三组各解剖4只,通过三组间的相互对照观察三种重金属的毒害作用。112 mice were randomly divided into 7 groups: one blank group, three poisoning groups and three experimental groups, with 16 mice in each group. The blank group was gavaged with normal saline for 2 weeks, and the poisoning group and the experimental group were gavaged with Pb and Cd solutions for 2 weeks, respectively. After each week, 4 rats in each of the three groups were dissected, and the toxic effects of the three heavy metals were observed by comparison among the three groups.

(2)称重及喂食(2) Weighing and feeding

每天早上9点开始对小鼠进行称重,记录下各小鼠的体重。称重完成后,按每组小鼠体重与数量喂食鼠粮(每只小鼠白天饲养量为2g/只,傍晚饲养量则为3g/只),并保证小鼠足够的凉开水。Mice were weighed every morning starting at 9:00 am, and the body weight of each mouse was recorded. After the weighing, the mice in each group were fed with rat food (2g/mice in the daytime and 3g/mice in the evening) according to the weight and quantity of each group of mice, and ensured that the mice had enough cold boiled water.

(3)灌胃(3) gavage

早上10点开始按当天小鼠的体重进行灌胃。空白组灌胃生理盐水,铅中毒组和试验组灌胃10mg/L醋酸铅,镉中毒组和试验组灌胃0.1mg/L镉溶液,按1ml/10g的量注射。From 10:00 in the morning, the mice were given intragastrically according to the body weight of the day. The blank group was given normal saline, the lead poisoning group and the test group were given 10 mg/L lead acetate, and the cadmium poisoning group and the test group were given 0.1 mg/L cadmium solution by gavage, and injected at a volume of 1 ml/10 g.

1.2 肠道菌群的培养1.2 Culture of intestinal flora

(1)粪便的收集(1) Collection of feces

在小鼠腹腔注射之前,采用腹部按摩的方式收集每只小鼠的粪便,放在已经灭菌过的离心管中,做好标记。收集频率为2天一次。Before the mouse intraperitoneal injection, the feces of each mouse were collected by abdominal massage, placed in a sterilized centrifuge tube, and marked. The frequency of collection is once every 2 days.

(2)粪便处理(2) Excrement treatment

将收集到的粪便称取0.1g溶于9.9ml水中稀释100倍,并立刻转移至超净工作台进行梯度稀释,稀释梯度为106。Weigh 0.1 g of the collected feces and dissolve it in 9.9 ml of water to dilute 100 times, and immediately transfer it to the ultra-clean workbench for gradient dilution. The dilution gradient is 106.

(3)菌群培养(3) Bacteria culture

在超净工作台上将四种灭完菌的培养基倒好四种平板,打开紫外灯照射15分钟,等平板冷却后迅速涂布接种,做好标记,静置10分钟。将两种厌氧菌培养皿(乳杆菌、双歧杆菌)用密封条密封,连同所有培养皿一起放入恒温培养箱中,于37℃条件下培养48小时。Pour the four kinds of sterilized culture medium into four kinds of plates on the ultra-clean workbench, turn on the ultraviolet light for 15 minutes, and quickly spread the inoculation after cooling the plates, make a mark, and let it stand for 10 minutes. The two kinds of anaerobic bacteria culture dishes (Lactobacillus, Bifidobacterium) were sealed with sealing strips, put into a constant temperature incubator together with all the culture dishes, and cultivated at 37 °C for 48 hours.

(4)菌群计数(4) bacterial count

48小时后取出所有培养皿,对四种菌群乳杆菌、双歧杆菌、大肠杆菌、肠球菌计数并记录。After 48 hours, all petri dishes were taken out, and the four bacterial groups Lactobacillus, Bifidobacterium, Escherichia coli, and Enterococcus were counted and recorded.

1.3 Pb、Cd含量测定1.3 Determination of Pb and Cd content

(1)解剖小鼠(1) Dissect mice

将挑选为解剖用的小鼠单独分开,采用断颈处死法将小鼠一一处死,再用75%酒精浸泡5分钟,转移至超净工作台上解剖。取出的肾脏放入无菌包装袋中,转移到-20℃冰箱保存。Mice selected for dissection were separated individually, and the mice were sacrificed by cervical dislocation, soaked in 75% alcohol for 5 minutes, and transferred to an ultra-clean workbench for dissection. The removed kidneys were placed in sterile packaging bags and stored in a -20°C refrigerator.

(2)消解器官(2) Digestion organs

取出小鼠肾脏器官,精密称定,置于50ml聚四氟乙烯坩埚中,加硝酸10ml加盖浸泡过夜,将坩埚置于电热板上于200℃消解,并间断滴加过氧化氢,直至产生黄棕色烟转为白色烟。最终溶液为澄明无色或略带黄色,加水约10ml继续加热驱酸,加热至近干,冷却,加入蒸馏水转移至50ml容量瓶中,用蒸馏水稀释至刻度,定容。Take out the mouse kidney organ, accurately weigh it, put it in a 50ml polytetrafluoroethylene crucible, add 10ml of nitric acid and cover it and soak it overnight, place the crucible on an electric hot plate to digest at 200 °C, and intermittently add hydrogen peroxide dropwise until it produces Yellow-brown smoke turned to white smoke. The final solution is clear and colorless or slightly yellow, add about 10ml of water and continue to heat to drive off the acid, heat to near dryness, cool, add distilled water and transfer to a 50ml volumetric flask, dilute to the mark with distilled water, and set the volume.

(3)标准曲线的制定(3) Establishment of standard curve

1)Pb标准溶液的配制1) Preparation of Pb standard solution

量取0.1 mg/mL的Pb单元素储备液10 mL,用100 mL容量瓶进行定容,摇匀后,得到Pb的标准贮备溶液,其浓度为10 μg/mL。取五个干燥后洁净的50 mL容量瓶,用移液枪分别向其中移入10 μg/mL Pb的标准贮备液1 mL、2 mL、3 mL、4 mL、5 mL、6 mL,然后分别定容至刻度,摇匀,则五个容量瓶中Pb的标准序列浓度分别为0.2 μg/mL、0.4 μg/mL、0.6 μg/mL、0.8μg/mL、1.0 μg/mL、1.2 μg/mL,分别贴上浓度标签,得到Pb标准曲线如图2所示。Measure 10 mL of 0.1 mg/mL Pb single-element stock solution, use a 100 mL volumetric flask to dilute to volume, and shake well to obtain a standard stock solution of Pb with a concentration of 10 μg/mL. Take five dry and clean 50 mL volumetric flasks, and transfer 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, and 6 mL of standard stock solution of 10 μg/mL Pb into them with a pipette, and then determine Volume to the mark, shake well, the standard serial concentrations of Pb in the five volumetric flasks are 0.2 μg/mL, 0.4 μg/mL, 0.6 μg/mL, 0.8 μg/mL, 1.0 μg/mL, 1.2 μg/mL, respectively. Label the concentration respectively, and obtain the standard curve of Pb as shown in Figure 2.

2)Cd标准溶液的配制2) Preparation of Cd standard solution

量取0.1 mg/mL的Cd单元素储备液2 mL,用100 mL容量瓶进行定容,摇匀后,得到Cd的标准贮备溶液,其浓度为2μg/mL。取五个干燥后洁净的50 mL容量瓶,用移液枪分别向其中移入2μg/mL Cd的标准贮备液0.25 mL、1.25 mL、2.5 mL、5 mL、7.5 mL、10 mL,然后分别定容至刻度,摇匀,则五个容量瓶中Cd的标准序列浓度分别为0.01 μg/mL、0.05 μg/mL、0.1 μg/mL、0.2 μg/mL、0.3 μg/mL、0.4 μg/mL ,分别贴上浓度标签,得到Cd标准曲线如图3所示。Measure 2 mL of 0.1 mg/mL Cd single-element stock solution, use a 100 mL volumetric flask to dilute to volume, and shake well to obtain a standard stock solution of Cd with a concentration of 2 μg/mL. Take five dry and clean 50 mL volumetric flasks, and use a pipette to transfer 0.25 mL, 1.25 mL, 2.5 mL, 5 mL, 7.5 mL, and 10 mL of standard stock solution of 2 μg/mL Cd into them respectively, and then adjust the volumes respectively. to the mark, shake well, the standard serial concentrations of Cd in the five volumetric flasks are 0.01 μg/mL, 0.05 μg/mL, 0.1 μg/mL, 0.2 μg/mL, 0.3 μg/mL, 0.4 μg/mL, respectively. Label the concentration and get the Cd standard curve as shown in Figure 3.

4)数据处理4) Data processing

根据各重金属浓度标准曲线,计算出样液中重金属的含量。分析肾中的重金属富集情况。According to the standard curve of each heavy metal concentration, the content of heavy metals in the sample solution was calculated. Analysis of heavy metal enrichment in kidneys.

2、灌胃小鼠益肠寿口服液2. Gavage the mice with Yichangshou Oral Liquid

2.1 灌胃益肠寿口服液2.1 Gavage Yichangshou Oral Liquid

(1)分组(1) Grouping

经过前两周实验,每组只剩下8只小鼠,三组共计72只。接下来空白组灌胃生理盐水2周,中毒组灌胃生理盐水2周,试验组灌胃益肠寿口服液2周,每周结束后三组各解剖4只,通过三组间的相互对照观察益肠寿口服液的解毒效果。After the first two weeks of the experiment, there were only 8 mice left in each group, for a total of 72 mice in the three groups. Next, the blank group was given normal saline for 2 weeks, the poisoned group was given normal saline for 2 weeks, and the experimental group was given Yichangshou Oral Liquid for 2 weeks. After each week, four animals in each of the three groups were dissected. To observe the detoxification effect of Yichangshou Oral Liquid.

(2)称重及喂食(2) Weighing and feeding

每天早上9点开始对小鼠进行称重,记录下各小鼠的体重。称重完成后,按每组小鼠体重与数量喂食鼠粮(每只小鼠白天饲养量为2g/只,傍晚饲养量则为3g/只),并保证小鼠足够的凉开水。Mice were weighed every morning starting at 9:00 am, and the body weight of each mouse was recorded. After the weighing, the mice in each group were fed with rat food (2g/mice in the daytime and 3g/mice in the evening) according to the weight and quantity of each group of mice, and ensured that the mice had enough cold boiled water.

(3)小鼠灌胃(3) Mice gavage

早上10点开始按当天小鼠的体重进行灌胃。空白组灌胃生理盐水,中毒组灌胃生理盐水,试验组灌胃益肠寿口服液的水溶液,按0.1ml/10g的量灌胃。From 10:00 in the morning, the mice were given intragastrically according to the body weight of the day. The blank group was intragastrically administered with normal saline, the poisoned group was intragastrically administered with normal saline, and the experimental group was intragastrically administered an aqueous solution of Yichangshou Oral Liquid at a dose of 0.1ml/10g.

2.2 肠道菌群的培养2.2 Cultivation of intestinal flora

(1)粪便的收集(1) Collection of feces

在小鼠腹腔注射之前,采用腹部按摩的方式收集每只小鼠的粪便,放在已经灭菌过的离心管中,做好标记。收集频率为2天一次。Before the mouse intraperitoneal injection, the feces of each mouse were collected by abdominal massage, placed in a sterilized centrifuge tube, and marked. The frequency of collection is once every 2 days.

(2)粪便处理(2) Excrement treatment

将收集到的粪便称取0.1g溶于9.9ml水中稀释100倍,并立刻转移至超净工作台进行梯度稀释,稀释梯度为106。Weigh 0.1 g of the collected feces and dissolve it in 9.9 ml of water to dilute 100 times, and immediately transfer it to the ultra-clean workbench for gradient dilution. The dilution gradient is 106.

(3)菌群培养(3) Bacteria culture

在超净工作台上将四种灭完菌的培养基倒好四种平板,打开紫外灯照射15分钟,等平板冷却后迅速涂布接种,做好标记,静置10分钟。将两种厌氧菌培养皿(乳杆菌、双歧杆菌)用密封条密封,连同所有培养皿一起放入恒温培养箱中,于37OC条件下培养48小时。Pour the four kinds of sterilized culture medium into four kinds of plates on the ultra-clean workbench, turn on the ultraviolet light for 15 minutes, and quickly spread the inoculation after cooling the plates, make a mark, and let it stand for 10 minutes. The two kinds of anaerobic bacteria culture dishes (Lactobacillus, Bifidobacterium) were sealed with sealing strips, and put into a constant temperature incubator together with all the culture dishes, and cultivated at 37OC for 48 hours.

(4)菌群计数(4) bacterial count

48小时后取出所有培养皿,对四种菌群乳杆菌、双歧杆菌、大肠杆菌、肠球菌计数并记录。After 48 hours, all petri dishes were taken out, and the four bacterial groups Lactobacillus, Bifidobacterium, Escherichia coli, and Enterococcus were counted and recorded.

2.3 Pb、Cd含量测定2.3 Determination of Pb and Cd content

(1)解剖小鼠(1) Dissect mice

将挑选为解剖用的小鼠单独分开,采用断颈处死法将小鼠一一处死,再用75%酒精浸泡5分钟,转移至超净工作台上解剖。取出的肾脏放入无菌包装袋中,转移到-20℃冰箱保存。Mice selected for dissection were separated individually, and the mice were sacrificed by cervical dislocation, soaked in 75% alcohol for 5 minutes, and transferred to an ultra-clean workbench for dissection. The removed kidneys were placed in sterile packaging bags and stored in a -20°C refrigerator.

(2)消解器官(2) Digestion organs

取出小鼠肾脏器官,精密称定,置于50ml聚四氟乙烯坩埚中,加硝酸10ml加盖浸泡过夜,将坩埚置于电热板上于200℃消解,并间断滴加过氧化氢,直至产生黄棕色烟转为白色烟。最终溶液为澄明无色或略带黄色,加水约10ml继续加热驱酸,加热至近干,冷却,加入蒸馏水转移至50ml容量瓶中,用蒸馏水稀释至刻度,定容。Take out the mouse kidney organ, accurately weigh it, put it in a 50ml polytetrafluoroethylene crucible, add 10ml of nitric acid and cover it and soak it overnight, place the crucible on an electric hot plate to digest at 200 °C, and intermittently add hydrogen peroxide dropwise until it produces Yellow-brown smoke turned to white smoke. The final solution is clear and colorless or slightly yellow, add about 10ml of water and continue to heat to drive off the acid, heat to near dryness, cool, add distilled water and transfer to a 50ml volumetric flask, dilute to the mark with distilled water, and set the volume.

(3)数据处理(3) Data processing

测量三种重金属样品吸光度,根据各重金属浓度标准曲线,计算出样液中重金属的含量。分析肾脏中的重金属富集情况。The absorbance of the three heavy metal samples was measured, and the content of heavy metals in the sample solution was calculated according to the standard curve of each heavy metal concentration. Analysis of heavy metal enrichment in kidneys.

3、研究结果3. Research results

3.1 小鼠铅中毒情况3.1 Lead poisoning in mice

(1)体重变化(1) Weight change

如图4所示,空白组小鼠体重呈直线增长的状态,而灌胃醋酸铅,使小鼠铅中毒的第一周内,小鼠体重下降。四周内小鼠体重整体呈现上升状态,与中毒组相比,灌胃益肠寿口服液后体重有所恢复。As shown in Figure 4, the body weight of the mice in the blank group increased linearly, while the weight of the mice was decreased within the first week of lead poisoning by gavage with lead acetate. Within four weeks, the overall body weight of the mice increased. Compared with the poisoning group, the body weight recovered after gavage with Yichangshou Oral Liquid.

(2)肠道菌群变化(2) Changes in intestinal flora

如图5所示,在第十四天开始灌胃益肠寿口服液后,肠道内的肠道益生菌乳杆菌、双歧杆菌出现明显的增殖。As shown in Figure 5, after gavage of Yichangshou Oral Liquid was started on the fourteenth day, the intestinal probiotics Lactobacillus and Bifidobacterium in the intestinal tract increased significantly.

(3)肾脏器官铅含量(3) Lead content in kidney organs

如图6所示,铅中毒后,铅主要富集在肾脏中,灌胃益肠寿口服液后,肾脏中的铅含量下降。As shown in Figure 6, after lead poisoning, lead was mainly concentrated in the kidneys, and after gavage with Yichangshou Oral Liquid, the lead content in the kidneys decreased.

3.2 小鼠镉中毒情况3.2 Cadmium poisoning in mice

(1)体重变化(1) Weight change

如图7所示,空白组小鼠体重呈直线增长的状态,而灌胃镉溶液的小鼠第一周内体重出现明显的下降。四周内小鼠体重整体呈现上升状态,与中毒组相比,灌胃益肠寿口服液后对试验组小鼠恢复体重有促进作用。As shown in Figure 7, the body weight of the mice in the blank group increased linearly, while the body weight of the mice fed with cadmium solution decreased significantly in the first week. The overall body weight of the mice increased within four weeks. Compared with the poisoning group, the oral administration of Yichangshou Oral Liquid had a promoting effect on the weight recovery of the mice in the experimental group.

(2)肠道数量变化(2) Changes in the number of intestines

如图8所示,在第十四天开始灌胃益肠寿口服液后,肠道内的肠道益生菌乳杆菌、双歧杆菌出现明显的增殖。As shown in Figure 8, after gavage of Yichangshou Oral Liquid was started on the fourteenth day, the intestinal probiotics Lactobacillus and Bifidobacterium in the intestinal tract increased significantly.

(3)肾脏镉含量的变化(3) Changes in kidney cadmium content

如图9所示,镉中毒后,铅在肾脏中都有分布,灌胃益肠寿口服液后,肾脏中的镉含量下降。As shown in Figure 9, after cadmium poisoning, lead was distributed in the kidneys, and after gavage with Yichangshou Oral Liquid, the cadmium content in the kidneys decreased.

综上,从小鼠体重及外貌特征(皮毛等)的变化情况上看,Pb、Cd染毒对小鼠产生了危害作用,小鼠出现明显的食欲不振,精神萎靡,并出现了部分个体的死亡;对肾进行Pb、Cd含量的测定,发现其有显著上升,但是肠道菌群无显著变化。对染毒后的小鼠灌胃益肠寿口服液后发现,从体重及行为情况来看,有恢复健康的迹象,并且肾脏中Pb、Cd含量均有下降的趋势,肠道中乳杆菌、双歧杆菌数量也有所增加。In summary, judging from the changes in the body weight and appearance characteristics (fur, etc.) of the mice, Pb and Cd exposure had a harmful effect on the mice, and the mice showed obvious loss of appetite, lethargy, and some individuals died. ; The content of Pb and Cd in the kidney was measured, and it was found that there was a significant increase, but there was no significant change in the intestinal flora. After gavage with Yichangshou Oral Liquid, it was found that in terms of body weight and behavior, there were signs of recovery, and the contents of Pb and Cd in the kidneys decreased. The number of fidobacteria also increased.

4、结论4 Conclusion

根据上述的试验结果可知,服用该益肠寿口服液对重金属染毒的促排、解毒有一定的正向作用,且有促进肠道内的肠道益生菌乳杆菌、双歧杆菌增殖的作用,具体效果包括:According to the above test results, taking the Yichangshou oral liquid has a certain positive effect on the excretion and detoxification of heavy metal poisoning, and has the effect of promoting the proliferation of intestinal probiotics Lactobacillus and Bifidobacterium in the intestinal tract. Specific effects include:

(1)益肠寿口服液一方面具有较强重金属吸附能力,相较其他重金属促排剂,本申请的益肠寿口服液用于机体中多种重金属的促排均具有较好的效果,同时因其生物相容性好而毒副作用小。(1) Yichangshou oral liquid has strong heavy metal adsorption capacity on the one hand, and compared with other heavy metal excretion promoters, the Yichangshou oral liquid of the present application has a good effect in promoting the excretion of various heavy metals in the body, At the same time, because of its good biocompatibility, the toxicity and side effects are small.

(2)另一方面,本申请的益肠寿口服液能改善肠道菌群组成,促进肠道益生菌乳杆菌、双岐杆菌的增殖。(2) On the other hand, the Yichangshou oral liquid of the present application can improve the composition of intestinal flora and promote the proliferation of intestinal probiotics Lactobacillus and Bifidobacterium.

其中,乳杆菌是一类重要的肠道益生菌,例如普遍存在于脊椎动物中的罗伊氏乳杆菌,它具有以下几种有益作用,第一,罗伊氏乳杆菌可以产生抗菌分子,能够抑制病原微生物的定殖并重塑共生微生物群;第二,罗伊氏乳杆菌可以使宿主免疫系统受益;第三,加强肠屏障的能力,罗伊氏乳杆菌的定植可能会减少从肠腔到组织的微生物易位。因此,罗伊氏乳杆菌的直接补充或益生元调节可能是预防和治疗炎性疾病的有效途径。Among them, Lactobacillus reuteri is an important type of intestinal probiotics. For example, Lactobacillus reuteri, which is ubiquitous in vertebrates, has the following beneficial effects. First, Lactobacillus reuteri can produce antibacterial molecules that can Inhibits the colonization of pathogenic microorganisms and remodels the commensal microbiota; second, L. reuteri may benefit the host immune system; Microbial translocation to tissues. Therefore, direct supplementation or prebiotic modulation of Lactobacillus reuteri may be an effective way to prevent and treat inflammatory diseases.

双歧杆菌(Bifidobacterium)作为重要的肠道益生菌,拥有多种益生功能,包括改善免疫系统紊乱导致的肠道疾病,比如炎症性肠病、溃疡性结肠炎、克罗恩病、结肠袋炎等;粘附在肠道上皮细胞并分泌抗菌肽,同时增加粘液层厚度,抑制病原菌侵入肠道;清除自由基、提高宿主抗氧化酶活性、减少血清和肝脏丙二醛的含量,从而缓解机体的氧化损伤,延缓衰老。As an important intestinal probiotic, Bifidobacterium has a variety of probiotic functions, including improving intestinal diseases caused by immune system disorders, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, pouchitis It adheres to intestinal epithelial cells and secretes antimicrobial peptides, while increasing the thickness of the mucus layer and inhibiting the invasion of pathogenic bacteria into the intestine; scavenging free radicals, increasing the activity of host antioxidant enzymes, reducing the content of serum and liver malondialdehyde, thereby relieving the body oxidative damage and delay aging.

据研究,婴儿肠道中双歧杆菌占绝对优势达99%,健康人(26-28岁)肠道中双歧杆菌只有14.8%,而老人仅为3.2%。益生菌如双歧杆菌、乳杆菌,是通过定殖在人体内,改变宿主某一部位菌群组成的一类对宿主有益的活性微生物,通过调节宿主黏膜与系统免疫功能或通过调节肠道内菌群平衡,促进食物消化吸收,防止便秘,合成维生素,从而增强人体免疫力和提高机体抗氧化水平的作用。According to research, the bifidobacteria in the intestinal tract of infants account for 99% of the total, while the intestinal bifidobacteria of healthy people (26-28 years old) is only 14.8%, and that of the elderly is only 3.2%. Probiotics, such as Bifidobacterium and Lactobacillus, are a class of active microorganisms that are beneficial to the host by colonizing the human body and changing the composition of a certain part of the host's flora. Group balance, promote food digestion and absorption, prevent constipation, synthesize vitamins, thereby enhancing human immunity and improving the body's antioxidant level.

本申请的益肠寿口服液能改善肠道菌群组成,促进肠道益生菌乳杆菌、双岐杆菌的增殖,肠道益生菌的增殖首先可以维持肠道菌群的稳态,其次可以与重金属作用降低重金属的毒害,进一步降低重金属对人体的损害。The Yichangshou oral liquid of the present application can improve the composition of intestinal flora, and promote the proliferation of intestinal probiotics Lactobacillus and Bifidobacterium. The effect of heavy metals reduces the toxicity of heavy metals and further reduces the damage of heavy metals to the human body.

本申请提供了一种益肠寿口服液及其制备方法与应用,制备的益肠寿口服液适用于处于亚健康状态的中老年人群。本申请的益肠寿口服液具有双重作用,一方面,可对镉、铅等重金属的吸附、促排,降低重金属对机体的毒害;另一方面,服用益肠寿口服液可对肠道益生菌乳杆菌、双歧杆菌有显著的增殖效果,肠道益生菌乳杆菌、双歧杆菌可促进肠道蠕动,通便润肠,缓解中老年人的便秘问题,抑制肠内腐败物质形成,利胆保肝,健脾宁心,从而达到延缓衰老、提高免疫力、改善机体生理状况的功效。另外,本申请的益肠寿口服液成本低、无毒副作用,可广泛推广使用。The application provides a Yichangshou oral liquid and a preparation method and application thereof, and the prepared Yichangshou oral liquid is suitable for middle-aged and elderly people in sub-health state. The Yichangshou oral liquid of the present application has dual functions. On the one hand, it can adsorb and promote the excretion of heavy metals such as cadmium and lead, and reduce the toxicity of heavy metals to the body; The bacteria Lactobacillus and Bifidobacterium have significant proliferation effects. Intestinal probiotics Lactobacillus and Bifidobacterium can promote intestinal peristalsis, laxative and moisturizing the intestines, relieve the constipation problem of middle-aged and elderly people, inhibit the formation of putrefactive substances in the intestine, and benefit the The gallbladder protects the liver, strengthens the spleen and calms the heart, so as to achieve the effects of delaying aging, improving immunity and improving the physiological condition of the body. In addition, the Yichangshou oral liquid of the present application has low cost, no toxic and side effects, and can be widely used.

以上所述的本申请实施方式并不构成对本申请保护范围的限定。The above-described embodiments of the present application do not limit the protection scope of the present application.

Claims (6)

1. An intestine-benefiting and life-prolonging oral liquid is characterized by comprising effective components, auxiliary material components and a solvent, wherein the effective components comprise carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose, the auxiliary material components comprise white paeony root, bitter orange, radix rehmanniae, cassia occidentalis, poria cocos and radish seed, and the solvent is water.
2. The intestine-benefiting and life-prolonging oral liquid according to claim 1, wherein the mass ratio of the carboxymethyl chitosan, the β -cyclodextrin, the fructo-oligosaccharide and the stachyose is 1:1:2:1, and the mass ratio of the white paeony root, the bitter orange, the radix rehmanniae, the cassia occidentalis, the poria cocos and the radish seed is 1:1: 1.5: 1.5: 1.5: 2.
3. The intestine-benefiting and life-prolonging oral liquid as claimed in claim 2, wherein the effective components comprise, by weight, 5g of carboxymethyl chitosan, 5g of β -cyclodextrin, 10g of fructo-oligosaccharide and 5g of stachyose, and the auxiliary materials comprise, by weight, 5g of radix paeoniae alba, 5g of fructus aurantii, 7.5g of radix rehmanniae, 7.5g of semen cassiae torae, 7.5g of poria cocos and 10g of semen raphani.
4. The oral liquid for benefiting intestine and longevity according to claim 3, wherein the amount of the solvent is 200-300 ml.
5. A method for preparing the oral liquid for benefiting intestine and prolonging life as claimed in any one of the above claims 1-4, which comprises the steps of crushing and mixing auxiliary materials, preparing liquid medicine, introducing effective components, controlling viscosity and sterilizing,
wherein, the auxiliary material is smashed and is specifically included with the mixing process: pulverizing radix Paeoniae alba, fructus Aurantii, radix rehmanniae, semen Cassiae, Poria and Raphani semen, and mixing in a mixer to obtain mixed adjuvants;
the liquid medicine preparation process specifically comprises the following steps: adding appropriate amount of water into the mixed adjuvants, decocting at 80-95 deg.C for about 1 hr, filtering to remove residue, and collecting the upper layer medicinal liquid;
the step of introducing effective components comprises adding carboxymethyl chitosan, β -cyclodextrin, fructo-oligosaccharide and stachyose into the obtained medicinal liquid, stirring thoroughly until the effective components are dissolved in the medicinal liquid, and making into oral stock solution;
the viscosity control process specifically comprises the following steps: adjusting the viscosity of the oral stock solution to obtain oral liquid;
the sterilization process specifically comprises the following steps: sterilizing the oral liquid, wherein the sterilization time is 10-30 minutes, the sterilization temperature is 110-130 ℃, and the sterilization pressure is 1.0-1.2 kpa.
6. Use of an oral liquid according to any of claims 1 to 4, wherein the oral liquid is used as a beneficial additive in dairy products or health products for the middle-aged and elderly.
CN202010187906.4A 2020-03-17 2020-03-17 A kind of Yichangshou oral liquid and its preparation method and application Pending CN111437248A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010187906.4A CN111437248A (en) 2020-03-17 2020-03-17 A kind of Yichangshou oral liquid and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010187906.4A CN111437248A (en) 2020-03-17 2020-03-17 A kind of Yichangshou oral liquid and its preparation method and application

Publications (1)

Publication Number Publication Date
CN111437248A true CN111437248A (en) 2020-07-24

Family

ID=71629280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010187906.4A Pending CN111437248A (en) 2020-03-17 2020-03-17 A kind of Yichangshou oral liquid and its preparation method and application

Country Status (1)

Country Link
CN (1) CN111437248A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118593558A (en) * 2024-08-08 2024-09-06 北京和益源生物技术有限公司 Animal bifidobacterium and radish seed composition with synergistic effect of preventing and treating functional constipation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451457A (en) * 1981-02-18 1984-05-29 Kureha Kagaku Kogyo Kabushiki Kaisha Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria
CN104435666A (en) * 2014-11-05 2015-03-25 北京润康普瑞生物技术有限公司 Traditional Chinese medicine composition with effect of relaxing bowels, as well as preparation method and application thereof
CN110101711A (en) * 2019-04-18 2019-08-09 东华理工大学 A kind of removing toxic substances medicament and its application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451457A (en) * 1981-02-18 1984-05-29 Kureha Kagaku Kogyo Kabushiki Kaisha Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria
CN104435666A (en) * 2014-11-05 2015-03-25 北京润康普瑞生物技术有限公司 Traditional Chinese medicine composition with effect of relaxing bowels, as well as preparation method and application thereof
CN110101711A (en) * 2019-04-18 2019-08-09 东华理工大学 A kind of removing toxic substances medicament and its application

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118593558A (en) * 2024-08-08 2024-09-06 北京和益源生物技术有限公司 Animal bifidobacterium and radish seed composition with synergistic effect of preventing and treating functional constipation

Similar Documents

Publication Publication Date Title
CN104829738B (en) Application of sargassum graminifolium polysaccharide extract in improvement of intestinal flora and prevention and treatment of diabetes
CN102228151B (en) Traditional Chinese medicine feed additive for treating hypogonadism of male breeding stock and preparation method thereof
CN108743851A (en) A kind of preparation method and compound probiotic powder of compound probiotic powder
CN102618452B (en) Preparation method, composition and application of lactobacillus salivarius and its metabolites
TW202135848A (en) Traditional chinese medicine formula flora capsule, preparation method and use thereof in preparing medicine for treating type 2 diabetes
CN106490360A (en) One boar green feed additive and preparation method thereof
CN104436142B (en) A kind of Chinese medicine composition for treating pig epidemic diarrhea
CN108095066A (en) A kind of function ferment preparation method
CN111437248A (en) A kind of Yichangshou oral liquid and its preparation method and application
CN110172106A (en) A kind of peach gum polysaccharide iron and its application
CN108096443B (en) Medicine for eliminating toxins in livestock and poultry and improving immunity of organism, preparation method and application thereof
CN118452281A (en) Milk powder composition containing walnut peptide
CN117397806A (en) Composition for improving ratio of lactobacillus fermentum to conditional pathogenic bacteria in intestinal tract and application thereof
CN116268414A (en) Composition for improving gastrointestinal function and preventing constipation and application thereof
CN110192653A (en) A kind of preparation method of pregnant and lying-in women and children special-purpose probiotics
CN116210836A (en) Solid beverage composition containing probiotics and application thereof
CN102488767B (en) Compound composition for treating bacterial diarrhoea of livestock and poultry
CN102293251A (en) Cornus officinalis fruit milk
CN113243532A (en) Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof
CN105661224A (en) Lactobacillus containing drink and preparation method thereof
CN103071148A (en) Compound thymosin Alpha 1 injection for improving livability of piglet and preparation method
CN114403450B (en) Application of black fungus polysaccharide additive in inhibiting body metabolism odor production
CN118059188B (en) Bifidobacterium longum SF-B-60 metazoan bacterial agent and preparation method and application thereof
CN101912449B (en) Medicament for treating hepatitis and preparation technology thereof
CN115607614B (en) Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200724